Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.4.1: prohibited at all times. Non-Specified. [1]
S4.4.1 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Mechanism and its limits
SR9009 is described in metabolic research as a REV-ERB ligand, but experiments in cells lacking both REV-ERB proteins still found effects on viability, metabolism and gene expression. Effects of SR9009 therefore cannot be used as specific proof of REV-ERB activity. [2]
- Cell and genetic-model evidence does not establish clinical benefit, a human dose or a human toxicity rate.
Product evidence
A 2016 study verified SR9009 in one internet-sold product and investigated metabolism using human liver microsomes. This is direct evidence for that tested product, not a measure of current availability, purity or population exposure. [3]
- In-vitro metabolism is not a clinical efficacy or safety trial.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- SR9009 has REV-ERB-independent effects on cell proliferation and metabolism ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
- In Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011 ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.